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The low prevalence levels associated with lymphatic filariasis elimination pose a challenge for effective disease surveillance. As more 
countries achieve the World Health Organization criteria for halting mass treatment and move on to surveillance, there is increasing 
reliance on the utility of transmission assessment surveys (TAS) to measure success. However, the long-term disease outcomes after 
passing TAS are largely untested. Using 3 well-established mathematical models, we show that low-level prevalence can be main-
tained for a long period after halting mass treatment and that true elimination (0% prevalence) is usually slow to achieve. The risk 
of resurgence after achieving current targets is low and is hard to predict using just current prevalence. Although resurgence is often 
quick (<5 years), it can still occur outside of the currently recommended postintervention surveillance period of 4–6 years. Our 
results highlight the need for ongoing and enhanced postintervention monitoring, beyond the scope of TAS, to ensure sustained 
success.
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Elimination of lymphatic filariasis (LF), a filarial nematode in-
fection that falls under the umbrella of neglected tropical dis-
eases, has been on the global agenda since publication of a 1993 
report by the International Task Force for Disease Eradication 
that identified it as 1 of 6 human diseases deemed potentially 
eradicable with current tools [1]. This led to the adoption of 
World Health Organization (WHO) resolution 50.29 in 1997, 
calling for the elimination of LF as a public health problem, 
with mass drug administration (MDA) as the main strategy. 
WHO launched the Global Programme to Eliminate Lymphatic 
Filariasis in 2000 and the resulting global initiative has seen un-
precedented international scale up [2].
Elimination as a public health problem (EPHP) is oper-
ationalized for LF by the WHO as passing a series of trans-
mission assessment surveys (TAS) that were initially designed 
to test for a microfilariae (mf) prevalence of less than 1% in 
areas where Anopheles or Culex are the main vector; where 
Aedes is the main vector this is 0.5% [3]. As new diagnos-
tics have become available, the current measure used is an 
antigenemia prevalence of 2%, as a conservative proxy for the 
historical 1% mf prevalence. Current MDA guidelines advise 
a minimum of 5 rounds of treatment before a pre-TAS is used 
to determine whether a first full TAS should be conducted, 
known as TAS-1. MDA can be stopped if TAS-1 is passed. 
Two subsequent surveys must also be passed before EPHP 
can be validated, TAS-2 and TAS-3, each within 2–3 years of 
the previous assessment.
Reaching <1% mf prevalence was expected to naturally lead 
to elimination of transmission, following the example of epi-
demiological studies in China from the 1990s [4]. As of 2017, 
11 of the 73 countries listed by WHO as endemic for LF have 
been validated for EPHP, with 10 more under postintervention 
surveillance and 46 currently delivering ongoing MDA [5]. The 
required treatment duration can be considerably longer than 
the initially anticipated 5–6 years, possibly due to unfavorable 
transmission or suboptimal program performance [6]. Ten 
countries have yet to begin MDA [2, 6].
However, recent evidence suggests that the TAS is not ca-
pable of detecting ongoing transmission; an example is the 
low-level persistence in some regions of Sri Lanka despite 
passing TAS and validation of EPHP in 2016 [7]. These find-
ings prompt concerns that halting interventions could result in 
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low-level maintenance of infection, potentially leading to future 
resurgence.
Mathematical models can help to assess which conditions 
are most likely to lead to resurgence and estimate the likelihood 
of permanently halting transmission, by simulating different 
scenarios across a range of settings [8–13]. Resurgence is gener-
ally considered to refer to a return to baseline levels of infection 
endemicity following the cessation of MDA.
There is well-supported mathematical and biological theory 
suggesting a transmission breakpoint for helminth infections, 
such as LF, which rely on sexual reproduction inside the host 
[14]. Both male and female parasites are required for reproduc-
tion to occur, so infections with a low worm burden are less 
likely to be infectious. As overall prevalence is pushed down, 
the mean worm burden also decreases, leading to less onward 
transmission; eventually sustained transmission becomes non-
viable and the disease is expected to naturally die out. This is 
called the transmission breakpoint and is likely to depend on 
local transmission conditions, such as biting rate and expo-
sure heterogeneity, as well as biological disease characteris-
tics, such as the extrinsic inoculation period duration (ie, the 
time required for the parasite to develop in the vector) [15, 16]. 
Previous studies have suggested that the breakpoint may be sub-
stantially below 1% mf prevalence in a number of settings [17, 
18]. Stochastic extinction can still occur above this breakpoint 
but with lower probability [19]. If interventions are halted soon 
after reaching the breakpoint, low-level residual transmission 
will decline slowly and it can take a long time for the parasite 
population to go extinct.
For the current study, multiple modelling groups joined 
forces to investigate the determinants and timelines of resur-
gence and elimination, as well as the suitability of a 1% mf 
threshold. Three well-established transmission models were 
used to provide greater robustness to our predictions. We did 
not explicitly model the TAS, instead we focused on the impli-
cations of a 1% mf threshold, presenting results that could in-
form the present global situation and any future developments 
in transmission assessment methods. As an mf prevalence of 
<1% in sentinel and spot-check sites is used as the main criteria 
for implementing TAS [3], our results should be representative 
of post-MDA settings, although care should be taken when gen-
eralizing conclusions to assess TAS results, which currently use 
an antigenemia prevalence of 2% as a threshold.
METHODS
Through using models to simulate population and indi-
vidual trends in infection over time, we investigated a range of 
scenarios that start the MDA program in 2014 (baseline), do 
5 annual rounds, and examine the post-MDA period (2019–
2029) for all simulations that achieve the 1% mf threshold 1 year 
after the fifth round of treatment. We first stratified simulations 
into 3 categories: resurgence, true elimination, and low-level 
maintenance of infection (full definitions below). We then used 
the proportion of simulations in each category as estimates for 
outcome probabilities and used simulation trajectories to inves-
tigate timelines. We also tested a range of potential post-MDA 
markers of resurgence and elimination that could be used, the 
best of which are presented here.
Employed Mathematical Models
We used 3 published models of LF transmission: EPIFIL 
[9, 20], LYMFASIM [21, 22], and TRANSFIL [16, 23]. 
EPIFIL is a population-based deterministic model, while 
both LYMFASIM and TRANSFIL are stochastic individual-
based models. All 3 models are age structured; EPIFIL and 
TRANSFIL are implemented with a balanced birth-death 
process. A  small importation rate is used to allow mainte-
nance of low-level prevalence at equilibrium. The models 
capture the basic processes relevant to transmission of LF, 
such as vector density and biting rate, parasite lifecycle, and 
human exposure to the vectors. The formulation and param-
etrization of these models has been discussed previously [12] 
(see also Supplementary Material).
All models can be used to simulate the impact of annual MDA, 
considering the target coverage, systematic nonadherence pat-
terns (only in LYMFASIM and TRANSFIL, with slightly dif-
ferent, but equivalent, formulations [24]) and the efficacy of 
employed drugs.
Scenario Settings
Our simulations here are focused on areas with bancroftian filari-
asis and anopheles as the dominant vector species. We constrained 
the baseline mf prevalence before intervention to a range of 5% to 
15%, restricting our analysis to the simulations that achieved the 
1% mf threshold within the WHO-recommended 5 rounds of an-
nual MDA, with the treatment regime most common in the ma-
jority of African settings where Anopheles is the vector, which is a 
combination of ivermectin and albendazole. We provide additional 
simulation results for regions without onchocerciasis that use a 
treatment of diethylcarbamazine and albendazole [10, 25], as well 
as with Culex mosquitoes as the dominant vector (Supplementary 
Material). Individuals aged 5 years and above were used to calcu-
late mf prevalence. We excluded higher-prevalence areas because 
they usually do not reach the 1% mf threshold after 5 rounds. We 
also assumed a constant 34% bed net coverage throughout, with 
this coverage maintained post-MDA until the end of the simula-
tions in 2029.
We considered a broad range of population sizes, with each 
value drawn from a distribution representative of rural African 
communities. We assumed most populations are small (me-
dian  =  approximately 1500 individuals), but a handful of lo-
cations are highly populated (maximum = 12 000 individuals) 
(Supplementary Material). We assumed homogeneous mixing 
in these populations.
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In each model, there were a number of parameters that 
we expected to vary across different populations and set-
tings. These parameters were generally related to trans-
mission, such as vector-host ratio or vector density (see 
Supplementary Material for further details). For our simu-
lations, we drew values for these parameters from broad 
prior distributions, based on previous applications of these 
models [12].
Forward Simulations
We ran 100 000 simulations for each model. The models were 
run to endemic equilibrium before MDA, giving the base-
line for 2014, and we filtered simulations to generate a uni-
form distribution in the range between 5% and 15% baseline 
mf prevalence. We then simulated annual MDA treatment, 
with a 65% coverage for 5  years. We assumed that a single 
dose of ivermectin and albendazole kills 35% of adult worms, 
with 9 months of sterilization for surviving worms, and kills 
99% of mf [12]. We selected the simulations that achieved 
the 1% mf threshold by 2019: about 80% for EPIFIL, 11% 
for LYMFASIM, and 9% for TRANSFIL of all the runs in the 
baseline prevalence range in 2014 considered. It is important 
to note that we selected the simulations based on the true 
mf prevalence value in the population at 2019 and there was 
no sampling protocol simulated (ie, TAS). Selected simula-
tions were then run for another 10 years, until 2029, to assess 
resurgence.
Analysis of Simulation Results
We defined resurgence 10 years post-MDA as any single return 
to a greater than 1% mf prevalence during the last 5 years of 
this period (in this case, 2025–2029); simulations that fulfilled 
this criterion were classified as resurgent scenarios. For the sto-
chastic models, we can define true elimination as any instance 
where mf prevalence hits true zero in a population before 2029; 
in the deterministic model we defined theoretical elimination as 
an mf prevalence of below 0.1% by 2029. Anything in between 
resurgence and elimination was considered to be low-level 
maintenance which, due to long timelines to elimination, may 
still eventually reach zero prevalence.
Based on these definitions, we could identify which runs lead 
to resurgence and which do not. We used bootstrap to estimate 
a 95% confidence interval (CI) for the probability of resurgence. 
Moreover, we could calculate how many simulations achieved 
true elimination by 2029. The structural differences between the 
models give different information. EPIFIL is deterministic and 
thus we can use it to assess the likely threshold below which 
resurgence does not occur. The model is run in a Bayesian 
framework accounting for parameter uncertainty. The lowest 
mf prevalence value in this model that yields a resurgent simu-
lation was considered an estimate of the theoretical prevalence 
breakpoint for disease transmission [18, 26]. On the other hand, 
LYMFASIM and TRANSFIL are stochastic, and thus can inform 
the probability of resurgence and when it is likely to occur. The 
timing of resurgence was estimated by pooling the simulations 
from the 2 stochastic models and finding, for the resurgent 
simulations, the first year (after 2019) that mf prevalence rose 
above the threshold.
We then explored options of early warning signs for re-
surgence, that is are there particular trends that can inform 
whether resurgence is likely to occur? We looked at 2 possible 
relevant metrics that could be used to detect resurgence [27]: 
(1) prevalence 1 year after the last round of MDA, which in the 
model is true mf prevalence but would operationally be meas-
ured as antigenemia prevalence in TAS-1; and (2) difference in 
prevalence between measurements 1 and 3 years following the 
last MDA round (measures 2 years apart), which represents the 
difference in true mf prevalence in the time window between 
TAS-1 and TAS-2. It is important to note that the TAS is not 
designed to measure a difference in true prevalence in the pop-
ulation. For these metrics, we examined a range of thresholds 
that could be used to identify resurgence. For the first we ex-
plored a threshold between 0% and 1% mf prevalence; if above 
the threshold, simulations would be classified as resurgence. For 
the latter we looked at a difference in mf prevalence from −1% 
to 1%; a negative difference means an increase in prevalence, 
below the threshold a run would be classified as resurgence. We 
then plotted the receiver operating characteristic curve (ROC 
curve) for the range of possible thresholds considered for these 
2 metrics (Supplementary Material).
RESULTS
Figure 1 shows the model-predicted temporal trends in true mf 
prevalence, during and after 5 years of MDA with albendazole. 
Based on the lowest mf prevalence value in this model that 
yielded a resurgent simulation in EPIFIL, the theoretical prev-
alence breakpoint for disease transmission by this model was 
estimated at about 0.5% mf prevalence. Resurgence occurred in 
1.81% (95% CI, 1.37%–2.4%) of LYMFASIM runs and 0.46% 
(95% CI, 0.18%–0.89%) of TRANSFIL runs (Figure 1, red), while 
true elimination (0% mf prevalence by 2029; Figure 1, blue) was 
achieved in 24% of LYMFASIM runs and 16% of TRANSFIL 
runs. Conversely, approximately 75% of the LYMFASIM runs 
and 84% of the TRANSFIL runs saw maintained prevalence 
below the EPHP threshold without achieving true elimination 
10 years later. None of the EPIFIL runs reached the defined the-
oretical elimination threshold of <0.1% mf prevalence by 2029.
We only kept simulations below the 1% mf threshold in 
2019. When resurgence occurred it was fairly quick (Figure 2), 
with 75% (37/49) of the resurgent scenarios in the 2 stochastic 
models having an mf prevalence returning above the threshold 
in the first 5 years. However, resurgence may still occur as many 
as 10 years post-MDA, in the year 2029 itself.
To understand the predictability of resurgence, we investi-
gated the sensitivity and specificity of different metrics related 
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to prevalence with possible thresholds (Figure  3, black line). 
The first metric considered was prevalence a year after MDA. 
In 98% of runs with resurgence, the mf prevalence 1 year post-
MDA was above the EPIFIL-estimated threshold of 0.5% (true-
positive rate). However, mf prevalence was also above 0.5% in 
73% of runs not resulting in resurgence (false-positive rate). In 
other words, using a 0.5% threshold we can correctly classify 
most resurgent simulations; however, many nonresurgent simu-
lations would be also classified as resurgence.
The second metric we considered was the difference in mf 
prevalence measured 1 and 3 years after the last MDA round 
(Figure  3, grey line). A  negative value represents an increase 
in prevalence. An intuitive threshold of zero difference (no 
change) between the 2 years gives a high true-positive rate (ap-
proximately 84%) and a relatively low false-positive rate (17%). 
This cutoff would correctly classify simulations below the 
threshold (negative difference) as resurgence, while keeping a 
relatively small proportion of false alarms.
DISCUSSION
We have used 3 well-established models of LF transmission 
and control to investigate the potential dynamics of resurgence 
and elimination for low endemicity settings. In particular, we 
have focused on the likelihood and timeline of resurgence in 
scenarios representative of settings with Wuchereria bancrofti 
infections, with Anopheles mosquitoes as the dominant vector, 
and treatment regimens of ivermectin and albendazole.
Our simulations suggest that in situations such as the scenario 
considered here, with a range of baseline mf prevalence between 
5% and 15% before MDA, 5 rounds of annual albendazole cam-
paigns, achieving a 65% coverage and maintaining low-level 
vector control, resurgence is possible in populations reaching 
the 1% mf prevalence public health threshold. The likelihood of 
resurgence is found to be very rare in the 2 stochastic models, 
TRANSFIL and LYMFASIM, while the deterministic model, 
EPIFIL, suggests a theoretical transmission breakpoint below 
the EPHP threshold of 1% mf prevalence.
Obviously, resurgence will be more common in smaller popu-
lations (ie, below 1000 individuals); the 1% threshold means less 
than 10 people infected, and thus a few additional infections 
can lead to extreme prevalence fluctuations. However, there are 
a few large populations in which we also observe resurgence, 
and in those cases it represents a coincidentally large number of 
new infections after 5 rounds of MDA and reaching the EPHP 
threshold.
When resurgence occurs, it is most likely to be apparent 
within a few years of stopping MDA (75% in the first 5 years; 
Figure  2). A  2-year post-MDA difference in mf prevalence is 
shown to be a potentially useful indicator for anticipating re-
surgence. The current monitoring strategies recommend a fol-
low-up survey, TAS-2 conducted 2–3 years after TAS-1, and a 
third survey, TAS-3, after a similar time period following TAS-2 
[3]. However, the current TAS framework is not designed 
to detect a difference in prevalence, but if additional survey 
methods could be developed to support this, then they could 
fit sensibly within present TAS timeframes. Our results suggest 
such a survey structure could allow detection of resurgence in 
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Figure 1. Temporal trends in true microfilaria (mf) prevalence in the population for each individual run. In red are runs that are classified as resurgence, blue are runs that 
achieve true elimination in LYMFASIM and TRANSFIL (0% mf prevalence) or theoretical elimination in EPIFIL (≤0.1% mf prevalence),, and in grey are runs that by 2029 remain 
below the threshold but have not achieved true/theoretical elimination.
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Figure 2. Scaled density histogram of the year of resurgence, defined as the 
earliest year above the 1% microfilaria (mf) threshold. Simulations from the 2 sto-
chastic models were chosen for mf prevalence of <1% 1 year after mass drug ad-
ministration (MDA), in 2019, indicated by the dashed line, which represents the 
timing of transmission assessment survey 1.
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around 75% of cases but that the timescales of EPHP valida-
tion could result in up to 25% of resurgence events being missed 
(see Figure 2). Metrics such as the estimated mf prevalence and 
difference since the previous survey could be adapted to other 
diagnostics (ie, antigenemia) and help inform the likelihood of 
such resurgence events.
Aiming to test for mf prevalences of less than 1% would 
present difficulties with survey affordability and sample size 
but would allow for greater confidence in program success. 
However, if it was possible to measure 0.5% mf prevalence then 
this could be sufficient, in scenarios such as those investigated 
here, to be confident that resurgence is very unlikely to occur.
True elimination is a slow process and in the scenarios we 
considered, with a range of population sizes and prevalence 
values, many runs, although not resurging, are maintained 
below the threshold for over 10  years without reaching zero 
prevalence (up to 2029, the considered time horizon), even with 
continued vector control (assumed 34%). While true elimina-
tion is not achieved, there is always a small risk of resurgence, 
therefore careful monitoring of trends is key. Moreover, al-
though the small importation rate used in the simulations did 
not play a role in resurgence here, highly endemic neighboring 
areas could have stronger effects.
We have used multiple models, all of which have been previ-
ously validated against data, which allows us to capture a range 
of dynamics and provides robustness to our predictions. Our 
choice of definition for resurgence is conservative, including 
all scenarios where mf prevalence goes above 1% at any time 
across the 5-year period between 2025 and 2029. Because a 
large number of simulations have low population sizes, some 
of the detected resurgence events could represent a handful of 
additional cases due to stochastic fluctuations rather than a real 
increasing trend. This may lead to an overestimation of resur-
gence, but a conservative approach ensures we consider all po-
tentially resurging simulations in our analyses.
As we have considered a limited range of preintervention 
prevalences and restricted ourselves to scenarios that achieve the 
1% mf threshold within the minimum recommended 5 rounds 
of MDA, we would expect our results to provide a best-case sce-
nario of resurgence. As such, resurgence is likely to occur with 
higher frequency across highly endemic settings, although we 
would also expect this to be faster and hence potentially more 
easily detectable within the TAS framework. Qualitatively sim-
ilar results, with some minor differences, were obtained for 
additional simulations in settings with an albendazole drug 
combination and with Culex, rather than Anopheles, as the 
dominant vector (shown in the Supplementary Material).
Our results are based on an assumed knowledge of true mf 
prevalence and we do not directly model antigen tests or the TAS 
sampling process. In addition, our community-level simulations 
of prevalence are not necessarily directly comparable to the TAS 
use of school-based assessment across villages in a larger area.
Our work also highlights that it is not easy to predict resur-
gence or elimination based on current prevalence only, due to 
the lack of specificity; metrics such as prevalence difference are 
seen to be better indicators (ROC curve; Figure 3). This implies 
that ongoing monitoring is still required beyond TAS time-
lines to ensure reductions in disease are maintained and detect 
whether a break in transmission has been achieved.
In summary, resurgence is generally rare with fairly conserv-
ative assumptions; however, many instances occur outside of 
the TAS1–3 period, therefore careful monitoring, even 5 years 
after cessation of MDA, would be recommended. Achieving 
true elimination is a slow process, and even in a 10-year time 
horizon, many runs do not reach it. Our analysis is based on 
true mf prevalence and therefore reliable diagnostics are neces-
sary to detect possible resurgence rapidly.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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Figure 3. Receiver operating characteristic (ROC) curve showing the true-positive 
rate against false-positive rate of resurgence for a range of thresholds in 2 different 
metrics. Black line represents prevalence after mass drug administration (MDA), 
with a threshold ranging between 0% and 1%. Grey broken line represents the dif-
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